600 patients66,869 observations120 daysLIVE

Patient P-01716

Synthetic patientNBL-101 · Day 114 · 45–54 · M · baseline S14Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Deteriorating
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Unstable
Discontinuation risk
81%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S14
  2. Day 50 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 54 GI-04 recommendedGI Support Protocol GI-04
  4. Day 55 Patient acceptedStarted GI-04 in the companion
  5. Day 63 GI symptom burden −19% vs expectedGI Support Protocol GI-04
  6. Day 69 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 50.

Primary contributors, last 14 days
  • Nutritional resilience-9
  • GI instability+7
  • Inflammatory activity+7
  • Toxicity+7
  • Treatment adherence-4

What helped?

  • GI Support Protocol GI-04Day 54
    Result: symptom burden −19%
LIFE OS recommendation
Dietary Support Protocol NP-02
65%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 66% showed improvement
  • median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
55.6/100
worsening · +8.7 vs previous 14 d
Toxicity
Blood
53.2/100
stable · +0.0 vs previous 14 d
Sleep quality
Wearable
23.8/100
worsening · -4.4 vs previous 14 d
Energy level
Daily log
2.7/10
worsening · -0.2 vs previous 14 d
Stress level
Daily log
6.5/10
worsening · +0.4 vs previous 14 d
Steps
Wearable
6,555
worsening · -940 vs previous 14 d
Adherence
Companion
43.6 %
stable · -1.9 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 36 from the failing basin, 56 from restoration.

Would help
  • ME-01 Monitoring Escalation
    100% improved among 77 similar · onset 3 d · confidence 80%
  • NP-02 Dietary Support Protocol
    63% improved among 64 similar · onset 10 d · confidence 80%
  • SC-12 Supportive Compound
    76% improved among 51 similar · onset 6 d · confidence 80%
Would not help
  • Keep fat low
    GI +6.8 next day on high-intake days · n 20
  • Keep histamine low
    GI +6 next day on high-intake days · n 20
  • Keep simple carbs low
    GI +5.1 next day on high-intake days · n 14
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +6.8detractor · 95%
  • Histamine load
    +6detractor · 95%
  • Simple carbohydrates
    +5.1detractor · 95%
  • Insoluble fibre
    +3.9detractor · 87%
  • Spicy / capsaicin
    -0.3no signal · 15%
  • Alcohol
    +0.2no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity 90
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 56 and rising
    • WearableSleep 6.0 h, below personal baseline
  • Drug metabolism and exposure 60
    • DNACYP2D6 poor metabolizer → higher exposure
    • BloodToxicity index 53
  • Butyrate / short-chain fatty acid production 55
    • MicrobiomeButyrate capacity 41/100
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling 45
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 56
  • Autonomic recovery 20
    • WearableShort sleep window
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • CYP2D6 Poor metabolizer
    Higher exposure at standard dose
Microbiome
Shannon diversity 2.6 · butyrate capacity 41/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiNormal
  • Bacteroides fragilisHigh
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
44 ms
Sleep
6.1 h
Steps
7,146
Resting HR
68 bpm
Daily log: GI score 56, nutritional resilience 39, adherence 44.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • Keep the current walking rhythm
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0160420%S0171
P-0138620%S1370
P-0135220%S2070
P-0175021%S1669
P-0169926%S04GI-04improved69
P-0150821%S1868
P-0150922%S1768
P-0187521%S1167
P-0181721%S1467
P-0187724%S01CR-01improved67
P-0151520%S1666
P-0162921%S1966